DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Kulke MH. et al.
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differenziated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
Ann Oncol 2017;
28: 1309-1315
We do not assume any responsibility for the contents of the web pages of other providers.